4 research outputs found
Combat and Warfare in the Early Paleolithic and Medically Unexplained Musculo-Facial Pain in the 21st Century War Veterns and Active-Duty Military Personnel
In a series of recent articles, we
suggest that family dentists, military
dentists and psychiatrists with expertise
in posttraumatic stress disorder (especially in the Veterans Health Administration) are likely to see an increased
number of patients with symptomatic
jaw-clenching and early stages of tooth-
grinding (Bracha et al., 2005). Returning
warfighters and other returnees from
military deployment may be especially
at risk for high rates of clenching-
induced masticatory muscle disorders
at early stages of incisor grinding. The
literature we have recently reviewed
strongly supports the conclusion that
clenching and grinding may primarily
be a manifestation of experiencing
extreme fear or severe chronic distress
(respectively). We have recently
reviewed the clinical and paleoanthropological literature and have noted that
ancestral warfare and ancestral combat,
in the early Paleolithic Environment of
Evolutionary Adaptedness (EEA) may
be a neglected factor explaining the
conservation of the archaic trait of
bite-muscle strengthening. We have
hypothesized that among ancestral
warriors, jaw clenching may have
rapidly strengthened the two primary
muscles involved in biting, the masseter
muscles and the much larger temporalis muscles. The strengthening of
these muscles may have served the
purpose of enabling a stronger, deeper,
and therefore more lethal, defensive
bite for early Paleolithic humans. The
neuroevolutionary perspective presented here may be novel to many dentists. However, it may be useful in
patient education and in preventing
progression from jaw-clenching to
chronic facial pain
Clinical Researach Histomarkers for Objectively Estimating Premorbid Vagal Tone Chronology in Gulf War Veterans' Illness and in Acute Stres Reaction
n/
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses